Premium
Blood Plasma Concentration and Activity of Pancreatic Lipase, Pancreatic Trypsin, MMP‐9, and Elastase in Congestive Heart Failure
Author(s) -
Courelli Vasiliki,
Courelli Asimina,
Stimson Ella,
Modestino Augusta,
Mills Paul,
SchmidSchoenbein Geert
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.977.6
Subject(s) - medicine , trypsin , heart failure , proteases , pancreatic elastase , endocrinology , lipase , elastase , enzyme , chemistry , biochemistry
Recent evidence suggests that pancreatic digestive enzymes may be involved in several types of organ dysfunction. This may include heart disease, but no studies exist. We hypothesize that pancreatic trypsin, pancreatic lipase, MMP‐9, and elastase may be present in blood and cardiac muscle in patients with congestive heart failure (CHF). Pancreatic enzymes may leak out of the small intestinal lumen, enter the systemic circulation and, ultimately, cause damage of the heart muscle. Pancreatic proteases, such as trypsin, are capable of activating other proteases, such as MMP‐9. Blood was drawn from 20 patients (10 CHF and 10 non‐CHF patients) while at rest. Western Blots showed a significant increase in plasma pancreatic lipase, trypsin, and MMP‐9 levels for the CHF patients when compared to non‐CHF patients. Activity assay results showed a significant increase in plasma MMP‐2/9 activity levels in CHF compared to non‐CHF patients but no differences in trypsin and elastase activity. These pilot experiments suggest that elevated plasma trypsin, lipase, and MMP‐9 concentrations as well as plasma MMP2/9 activity are correlated with CHF, may play a role in the loss of cardiac function, and may serve as potential biomarkers for CHF. Support or Funding Information NIH Grants: 5 R01 HL073355‐01, GM 85072